Trade Immunome Inc - IMNM CFD

Immunome, Inc. Company profile

About Immunome Inc

Immunome, Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The Company is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Immunome Inc revenues was not reported. Net loss increased 22% to $16.9M. Higher net loss reflects General and administrative - Balancing increase from $2.3M to $6.3M (expense), Research & Development - Balancing value increase of 58% to $8.8M (expense), Stock-based Compensation in SGA increase from $208K to $1.3M (expense).